ANALISIS BIAYA DAN LUARAN KLINIK PENGGUNAAN HUMAN ALBUMIN PADA PASIEN SINDROM NEFROTIK DI RSUP Dr. KARIADI SEMARANG

Trisnawati, Sari and -, Tri Murti Andayani, Ph.D (2021) ANALISIS BIAYA DAN LUARAN KLINIK PENGGUNAAN HUMAN ALBUMIN PADA PASIEN SINDROM NEFROTIK DI RSUP Dr. KARIADI SEMARANG. Thesis thesis, Universitas Muhammadiyah Surakarta.

	PDF (Halaman Depan) HALAMAN DEPAN.pdf Download (1MB)
	PDF (Bab I) BAB I.pdf Download (345kB)
	PDF (Bab II) BAB II.pdf Restricted to Repository staff only Download (754kB) | Request a copy
	PDF (Bab III) BAB III.pdf Restricted to Repository staff only Download (403kB) | Request a copy
	PDF (Bab IV) BAB IV.pdf Restricted to Repository staff only Download (443kB) | Request a copy
	PDF (Bab V) BAB V.pdf Restricted to Repository staff only Download (255kB) | Request a copy
	PDF (Daftar Pustaka) DAFTAR PUSTAKA.pdf Download (434kB)
	PDF (Lampiran) LAMPIRAN.pdf Restricted to Repository staff only Download (3MB) | Request a copy
	PDF (Naskah Publikasi) NASKAH PUBLIKASI_SARI TRISNAWATI.pdf Download (1MB)
	PDF (Surat Pernyataan Publikasi) SURAT PERNYATAAN PUBLIKASI ILMIAH.pdf Restricted to Repository staff only Download (219kB) | Request a copy

Abstract

The use of human albumin in some conditions is still controversial. This research aims to determine the direct medical cost and clinical outcome as seen from changes in albumin levels. The research was conducted by cohort design through retrospective data tracing. Data collection is obtained from medical records and data from the financial department. The results of the study in the period 2017-2020 showed there were 177 cases of nephrotic syndrome patients given human albumin therapy and not given human albumin therapy with serum albumin levels between 2-3.5 g/dL. The highest prevalence in male was 118 (66.7%), there was a human albumin group of 95 patients and the group did not use human albumin 82 patients against nephrotic syndrome patients. Direct medical cost required for the use of human albumin is Rp13.254.041±Rp11.453.116 and Rp9.509.414±Rp11.131.763 for not using human albumin. Differences found in clinical outcomes based on changes in human albumin levels. At the average changes in albumin levels there was a significant difference in clinical outcomes cost (p < 0.05) at the measurement time on < 7 days and 15-21days, and there was no significant difference (p< 0.05) at the measurement time of 7-14 days and >21 days. Keywords : Cost analysis, Human albumin, Nephrotic Syndrome, direct medical cost

Item Type:	Karya ilmiah (Thesis)
Uncontrolled Keywords:	Analisis biaya, Human albumin, Sindrom Nefrotik, biaya medis langsung
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Fakultas Pasca Sarjana > Magister Farmasi
Depositing User:	SARI TRISNAWATI
Date Deposited:	14 Aug 2021 03:08
Last Modified:	14 Aug 2021 03:08
URI:	http://eprints.ums.ac.id/id/eprint/92564

Actions (login required)

View Item